- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00628914
Brain Mechanisms and Targeting Insomnia in Major Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A critical challenge in the management of major depressive disorder (MDD) is the delay between initiating treatment with an antidepressant medication and clinical improvement. Preliminary studies (Fava et al., 2006; Krystal et al., 2007) suggest that targeting insomnia with eszopiclone (ESZ) in patients receiving fluoxetine may lead to more rapid resolution of symptoms. Studies have not yet been able to differentiate between competing explanations of this phenomenon: whether co-treatment with ESZ actually accelerates changes in the brain associated with antidepressant treatment response, or if its effects on the insomnia component are confined to the symptomatic level ("masking"). As a non-benzodiazepine GABA-receptor agonist with FDA approval for long-term use in the treatment of sleep disturbances, ESZ is an appropriate agent for targeting insomnia in MDD without major concerns around the development of tolerance. Further research in co-treatment would be advanced by understanding the mechanism(s) underlying accelerated improvement.
Our prior work (Cook et al., 2001, 2002, 2005; Leuchter et al. 2002) has studied a new physiologic biomarker of response to SSRI and mixed-action antidepressants. The EEG-based cordance biomarker can detect the physiologic effects of successful antidepressant treatment at 48 hours, 1 week, and 2 weeks of treatment; in contrast, symptom differences between responders and non-responders did not separate until 4 weeks of treatment in our placebo-controlled trials. Additionally, the magnitude of early physiologic change was associated with the completeness of clinical response. Our biomarker has been independently studied and our findings replicated (Bareš et al., 2007). The cordance biomarker can be considered as a leading indicator or predictor of treatment outcome. As a non-invasive probe of brain physiology, it may detect early neurophysiologic changes associated with accelerated clinical response from eszopiclone.
Other research has reported that brain derived neurotrophic factor (BDNF) is reduced in many patients with MDD (Karege et al., 2002, 2005, Shimizu et al., 2003) and may rise during the course of treatment with antidepressant medication (e.g., Gonul et al., 2005; Yoshimura et al., 2007; Huang et al., 2007). BDNF-related neuroplasticity has been suggested as a mechanism by which medications can lead to mood improvement (Duman 2002; Manji et al., 2003). Sleep patterns have also been shown to have an impact on neuroplasticity (Taishi et al., 2001; cf. Benington & Frank, 2003). A simple acute phase-shift in sleep can impact BDNF levels (Sei 2003), suggesting that a link between sleep and symptomatic recovery from depression might operate via a BDNF mechanism and reflect changes in brain physiology.
While Krystal and colleagues (2007) previously reported that the beneficial clinical effects of 8 weeks of co-treatment did not diminish significantly in the two weeks following ESZ discontinuation, controlled studies have not examined outcomes in clinically-likely scenarios employing shorter co-treatment periods (e.g., 4 weeks, during which much of the acceleration occurs).
Based on these previous studies, this study will assess patients with MDD during treatment with an SSRI antidepressant, escitalopram (ESC), administered along with either ESZ or placebo (PBO), using (a) clinical symptom ratings, (b) serum levels of BDNF, (c) cognitive function, and (d) brain physiology with EEG.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- Semel Institute for Neuroscience and Human Behavior at UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients with non-psychotic, unipolar Major Depressive Disorder (MDD).
- A score of >14 on the HAM-D17.
- Presence of insomnia, manifest by a total score of ≥ 4 combining all three sleep disturbance items on the HAM-D17 scale.
- Age range: 18-64.
- Patients with suicidal ideation are eligible only if the thoughts of death or of life not being worth living are not accompanied by a plan or intention for self-harm.
Exclusion Criteria:
- Patient is mentally or legally incapacitated, unable to give informed consent.
- Patients who have a lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, MDD with psychotic features, or dementia (any etiology).
- Patients with diagnostic uncertainty or ambiguity (e.g. rule-out pseudodementia of depression) will be excluded.
- Patients with a current diagnosis of anorexia nervosa, bulimia nervosa, or obsessive compulsive disorder.
- Patients who have met diagnostic criteria for any current substance abuse disorder at any time in the 6 months prior to enrollment.
- Insomnia symptoms that have not responded to a previous trial of a sedativehypnotic prescription medication.
- Any history of seizures, brain surgery, skull fracture, significant head trauma, or previous abnormal EEG.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Open label escitalopram plus eszopiclone for 8 weeks
|
escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
Other Names:
|
OTHER: 2
Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
|
Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
Other Names:
|
PLACEBO_COMPARATOR: 3
Escitalopram plus placebo for 8 weeks
|
Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in cordance value
Time Frame: Visits 2-9
|
Visits 2-9
|
Change in cordance value
Time Frame: Visit 11
|
Visit 11
|
Change in cordance value
Time Frame: Visit 13
|
Visit 13
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Depression symptom severity
Time Frame: each visit
|
each visit
|
Serum BDNF
Time Frame: visits 2-9
|
visits 2-9
|
Cognitive testing
Time Frame: visits 2-7
|
visits 2-7
|
Serum BDNF
Time Frame: Visit 11
|
Visit 11
|
Serum BDNF
Time Frame: Visit 13
|
Visit 13
|
Cognitive testing
Time Frame: Visit 9
|
Visit 9
|
Cognitive testing
Time Frame: Visit 13
|
Visit 13
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ian A Cook, MD, Semel Institute for Neuroscience and Human Behavior at UCLA
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Mood Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Depression
- Depressive Disorder
- Sleep Initiation and Maintenance Disorders
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Hypnotics and Sedatives
- Antidepressive Agents, Second-Generation
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Citalopram
- Dexetimide
- Eszopiclone
Other Study ID Numbers
- ESRC973
- 07-11-013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
VA Office of Research and DevelopmentVA Connecticut Healthcare System; US Department of Veterans AffairsCompleted
-
NYU Langone HealthNational Institute of Nursing Research (NINR); National Institutes of Health...CompletedInsomniaUnited States
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
University of California, San FranciscoCompleted
-
Weill Medical College of Cornell UniversityWeill Cornell Medical College in QatarWithdrawn
-
Eisai Inc.CompletedInsomniaUnited States
-
SanofiCompletedInsomniaUnited States
-
National Yang Ming UniversityBened Biomedical Co., Ltd.Not yet recruiting
-
Leiden University Medical CenterNot yet recruiting
-
Weill Medical College of Cornell UniversityMARPACCompleted
Clinical Trials on escitalopram and eszopiclone
-
Eisai Co., Ltd.Completed
-
Eisai Co., Ltd.Completed
-
SunovionCompletedInsomnia | Attention Deficit Hyperactivity DisorderUnited States
-
SunovionCompletedInsomnia | Attention Deficit Hyperactivity DisorderUnited States
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Mclean HospitalCompleted
-
Beth Israel Deaconess Medical CenterTerminatedDiabetes | Glucose Intolerance | Prediabetes | PrediabeticUnited States
-
SunovionCompletedGeneralized Anxiety DisorderUnited States
-
Emory UniversitySunovionCompletedPoor Quality Sleep
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; SunovionCompleted
-
Laboratorios Andromaco S.A.Completed